Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018

SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
March 01, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Two Upcoming Investor Conferences in March

SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
January 04, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
December 21, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
December 07, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

SAN DIEGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
November 27, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
November 21, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference

SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
November 14, 2017 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
November 01, 2017 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Leadership Transition

– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,Dr. Sanjay Shukla Appointed President and CEO – SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE),...
September 27, 2017 08:00 ET | Source: aTyr Pharma Inc.

aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society

SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...